Protein O-glucosyltransferase 1 overexpression downregulates p16 in BT474 human breast cancer cells

Oncology Letters

Volumn 8, Issue 2, 2014, Pages 594-600

  Jin, Gang ^a,b   Cao, Zhigang ^c   Sun, Xilin ^a   Wang, Kai ^a   Huang, Tao ^a   Shen, Baozhong ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b The 211 Hospital of PLA   (China)

^c THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

BT474 human breast cancer cells; p16; Protein O glucosyltransferase 1; Smad3; Transforming growth factor 1

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; GLYCOSYLTRANSFERASE; PROTEIN O GLUCOSYLTRANSFERASE 1; PROTEIN P16; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CELL VIABILITY; CONTROLLED STUDY; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MYELODYSPLASTIC SYNDROME; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84902328512     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2197     Document Type: Article

References (37)

1. Takeuchi H, Fernández-Valdivia RC, Caswell DS, Nita-Lazar A, Rana NA, Garner TP, et al: Rumi functions as both a protein O-glucosyltransferase and a protein O-xylosyltransferase. Proc Natl Acad Sci USA 108: 16600-16605, 2011.
2. Fernandez-Valdivia R, Takeuchi H, Samarghandi A, Lopez M, Leonardi J, Haltiwanger RS and Jafar-Nejad H: Regulation of mammalian Notch signaling and embryonic development by the protein O-glucosyltransferase Rumi. Development 138: 1925-1934, 2011.
3. Sethi MK, Buettner FF, Ashikov A, Krylov VB, Takeuchi H, Nifantiev NE, et al: Molecular cloning of a xylosyltransferase that transfers the second xylose to O-glucosylated epidermal growth factor repeats of notch. J Biol Chem 287: 2739-2748, 2012.
4. Ma W, Du J, Chu Q, Wang Y, Liu L, Song M and Wang W: hCLP46 regulates U937 cell proliferation via Notch signaling pathway. Biochem Biophys Res Commun 408: 84-88, 2011.
5. Teng Y, Liu Q, Ma J, Liu F, Han Z, Wang Y and Wang W: Cloning, expression and characterization of a novel human CAP10-like gene hCLP46 from CD34(+) stem/progenitor cells. Gene 371: 7-15, 2006.
6. Wang Y, Chang N, Zhang T, Liu H, Ma W, Chu Q, et al: Overexpression of human CAP10-like protein 46 KD in T-acute lymphoblastic leukemia and acute myelogenous leukemia. Genet Test Mol Biomarkers 14: 127-133, 2010.
7. Pierelli L, Marone M, Bonanno G, Mozzetti S, Rutella S, Morosetti R, et al: Modulation of bcl-2 and p27 in human primitive proliferating hematopoietic progenitors by autocrine TGF-beta1 is a cell cycle-independent effect and influences their hematopoietic potential. Blood 95: 3001-3009, 2000.
8. Cipriano R, Kan CE, Graham J, Danielpour D, Stampfer M and Jackson MW: TGF-beta signaling engages an ATM-CHK2-p53-independent RAS-induced senescence and prevents malignant transformation in human mammary epithelial cells. Proc Natl Acad Sci USA 108: 8668-8673, 2001.
9. Bardeesy N, Morgan J, Sinha M, Signoretti S, Srivastava S, Loda M, et al: Obligate roles for p16(Ink4a) and p19(Arf)-p53 in the suppression of murine pancreatic neoplasia. Mol Cell Biol 22: 635-643, 2002.
10. Liu P, Zhang C, Feng JB, Zhao YX, Wang XP, Yang JM, et al: Cross talk among Smad, MAPK, and integrin signaling pathways enhances adventitial fibroblast functions activated by transforming growth factor-beta1 and inhibited by Gax. Arterioscler Thromb Vasc Biol 28: 725-731, 2008.
11. Bran GM, Sommer UJ, Goessler UR, Hörmann K, Riedel F and Sadick H: TGF-β1 antisense impacts the SMAD signalling system in fibroblasts from keloid scars. Anticancer Res 30: 3459-3463, 2010.
12. Janknecht R, Wells NJ and Hunter T: TGF-beta-stimulated cooperation of smad proteins with the coactivators CBP/p300. Genes Dev 12: 2114-2119, 1998.
13. Kim RH, Wang D, Tsang M, Martin J, Huff C, de Caestecker MP, et al: A novel smad nuclear interacting protein, SNIP1, suppresses p300-dependent TGF-beta signal transduction. Genes Dev 14: 1605-1616, 2000.
14. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y and Wang XF: Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 92: 5545-5549, 1995.
15. McConnell BB, Gregory FJ, Stott FJ, Hara E and Peters G: Induced-expression of p16(INK4a) inhibits both CDK4-and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes. Mol Cell Biol 19: 1981-1989, 1999.
16. Aprelikova O, Xiong Y and Liu ET: Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase. J Biol Chem 270: 18195-18197, 1995.
17. Bockstaele L, Kooken H, Libert F, Paternot S, Dumont JE, de Launoit Y, et al: Regulated activating Thr172 phosphorylation of cyclin-dependent kinase 4(CDK4): its relationship with cyclins and CDK 'inhibitors'. Mol Cell Biol 26: 5070-5085, 2006.
18. Noh SJ, Li Y, Xiong Y and Guan KL: Identification of functional elements of p18INK4C essential for binding and inhibition of cyclin-dependent kinase (CDK) 4 and CDK6. Cancer Res 59: 558-564, 1999.
19. Omura-Minamisawa M, Diccianni MB, Chang RC, Batova A, Bridgeman LJ, Schiff J, et al: p16/p14(ARF) cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced stage disease. Clin Cancer Res 7: 3481-3490, 2001.
20. Yao J, Pollock RE, Lang A, Tan M, Pisters PW, Goodrich D, et al: Infrequent mutation of the p16/MTS1 gene and overexpression of cyclin-dependent kinase 4 in human primary soft-tissue sarcoma Clin Cancer Res 4: 1065-1070, 1998.
21. Kubo A, Nakagawa K, Varma RK, Conrad NK, Cheng JQ, Lee WC, et al: The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. Clin Cancer Res 5: 4279-4286, 1999.
22. Stein GH, Drullinger LF, Soulard A and Dulić V: Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol Cell Biol 19: 2109-2117, 1999.
23. Akervall J, Bockmühl U, Petersen I, Yang K, Carey TE and Kurnit DM: The gene ratios c-MYC:cyclin-dependent kinase (CDK)N2A and CCND1:CDKN2A correlate with poor prognosis in squamous cell carcinoma of the head and neck. Clin Cancer Res 9: 1750-1755, 2003.
24. Mihira H, Suzuki HI, Akatsu Y, Yoshimatsu Y, Igarashi T, Miyazono K and Watabe T: TGF-β-induced mesenchymal transition of MS-1 endothelial cells requires Smad-dependent cooperative activation of Rho signals and MRTF-A. J Biochem 151: 145-156, 2012.
25. Zhang SJ, Endo S, Ichikawa T, Washiyama K and Kumanishi T: Frequent deletion and 5' CpG island methylation of the p16 gene in primary malignant lymphoma of the brain. Cancer Res 58: 1231-1237, 1998.
26. Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D and Barrett JC: Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci USA 93: 13742-13747, 1996.
27. Dreyling MH, Bullinger L, Ott G, Stilgenbauer S, Müller-Hermelink HK, Bentz M, et al: Alterations of the Cyclin D1/p16-pRB Pathway in mantle cell lymphoma. Cancer Res 57: 4608-4614, 1997.
28. FitzGerald MG, Harkin DP, Silva-Arrieta S, MacDonald DJ, Lucchina LC, Unsal H, et al: Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci USA 93: 8541-8545, 1996.
29. Cai D, Byth KF and Shapiro GI: AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9. Cancer Res 66: 435-444, 2006.
30. Park DS, Morris EJ, Bremner R, Keramaris E, Padmanabhan J, Rosenbaum M, et al: Involvement of retinoblastoma family members and E2F/DP complexes in the death of neurons evoked by DNA damage. J Neurosci 20: 3104-3114, 2000.
31. Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J and Bartek J: The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 56: 5475-5483, 1996.
32. Tsukiyama-Kohara K, Toné S, Maruyama I, Inoue K, Katsume A, Nuriya H, et al: Activation of the CKI-CDK-Rb-E2F pathway in full genome hepatitis C virus-expressing cells. J Biol Chem 279: 14531-14541, 2004.
33. Guo K and Walsh K: Inhibition of myogenesis by multiple cyclin-Cdk complexes. Coordinate regulation of myogenesis and cell cycle activity at the level of E2F. J Biol Chem 272: 791-797, 1997.
34. Ojima H, Saito K, Yamauchi H, Yamaki E, Idetu A, Hosouchi Y, Nishida Y, et al: P16 protein abnormality in Epstein-Barr virus-associated gastric carcinomas. Anticancer Res 26: 933-937, 2006.
35. Alani RM, Young AZ and Shifflett CB: Id1 regulation of cellular senescence through transcriptional repression of p16/Ink4a. Proc Natl Acad Sci USA 98: 7812-7816, 2001.
36. Yuen PW, Man M, Lam KY and Kwong YL: Clinicopathological significance of p16 gene expression in the surgical treatment of head and neck squamous cell carcinomas. J Clin Pathol 55: 58-60, 2002.
37. Singh RP, Agarwal C and Agarwal R: Inositol hexaphosphate inhibits growth, and induces G1 arrest and apoptotic death of prostate carcinoma DU145 cells: modulation of CDKI-CDK-cyclin and pRb-related protein-E2F complexes. Carcinogenesis 24: 555-563, 2003.